Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker DSGN
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Steven A. Cohen | 2.37M | 3.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 2.37M | 3.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Point72 Asset Management, L.P. | 2.37M | 3.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G | DSGN Design Therapeutics, Inc. | Alex Silverstein | 5.96M | 9.5% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | DSGN Design Therapeutics, Inc. | Sirenia Capital Management LP | 5.96M | 9.5% | SCHEDULE 13G ↗ |
| Jun 9, 2026 | SCHEDULE 13G | DSGN Design Therapeutics, Inc. | Steven A. Cohen | 3.20M | 5.1% | SCHEDULE 13G ↗ |
| Jun 9, 2026 | SCHEDULE 13G | DSGN Design Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 3.20M | 5.1% | SCHEDULE 13G ↗ |
| Jun 9, 2026 | SCHEDULE 13G | DSGN Design Therapeutics, Inc. | Point72 Asset Management, L.P. | 3.20M | 5.1% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Steven A. Cohen | 2.72M | 4.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 2.72M | 4.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Point72 Asset Management, L.P. | 2.72M | 4.4% | SCHEDULE 13G/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | George Simeon | 6.61M | 10.7% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | SR One Capital Management, LLC | 6.53M | 10.6% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | SR One Capital Partners I, LP | 6.53M | 10.6% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | SR One Capital Fund I Aggregator, LP | 6.53M | 10.6% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Steven A. Cohen | 5.37M | 9.4% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 5.37M | 9.4% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Point72 Asset Management, L.P. | 5.37M | 9.4% | SCHEDULE 13G/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | William Arsani | 2.52M | 4.4% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | Logos GP LLC | 1.50M | 2.6% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | Logos Global Master Fund LP | 1.50M | 2.6% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | Logos Global Management GP LLC | 2.50M | 4.4% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | Logos Global Management LP | 2.50M | 4.4% | SCHEDULE 13D/A ↗ |
| Nov 12, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | William Arsani | 3.25M | 5.7% | SCHEDULE 13D/A ↗ |
| Nov 12, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | Logos GP LLC | 2.24M | 3.9% | SCHEDULE 13D/A ↗ |
| Nov 12, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | Logos Global Master Fund LP | 2.24M | 3.9% | SCHEDULE 13D/A ↗ |
| Nov 12, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | Logos Global Management GP LLC | 3.24M | 5.7% | SCHEDULE 13D/A ↗ |
| Nov 12, 2025 | SCHEDULE 13D/A (amended) | DSGN Design Therapeutics, Inc. | Logos Global Management LP | 3.24M | 5.7% | SCHEDULE 13D/A ↗ |
| Aug 28, 2025 | SCHEDULE 13G | DSGN Design Therapeutics, Inc. | Steven A. Cohen | 2.94M | 5.2% | SCHEDULE 13G ↗ |
| Aug 28, 2025 | SCHEDULE 13G | DSGN Design Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 2.94M | 5.2% | SCHEDULE 13G ↗ |
| Aug 28, 2025 | SCHEDULE 13G | DSGN Design Therapeutics, Inc. | Point72 Asset Management, L.P. | 2.94M | 5.2% | SCHEDULE 13G ↗ |
| Feb 7, 2025 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Jason Howerton | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 7, 2025 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Star Irrevocable Trust #1 dated April 22, 2019 | 3.83M | 6.9% | SCHEDULE 13G/A ↗ |
| Feb 7, 2025 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Jason Howerton | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 7, 2025 | SCHEDULE 13G/A (amended) | DSGN Design Therapeutics, Inc. | Light Irrevocable Trust #1 dated April 22, 2019 | 3.83M | 6.9% | SCHEDULE 13G/A ↗ |
35 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 8:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances